⌘K

Home/Filings/4/0001179110-21-002366

4//SEC Filing

Chen Hongming 4

Accession 0001179110-21-002366

CIK 0001479419other

View on SEC.gov Company Profile

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 5:35 PM ET

Size

6.6 KB

Accession

0001179110-21-002366

Insider Transaction Report

Form 4

Period: 2021-02-25

Kala Pharmaceuticals, Inc.KALA

Chief Scientific Officer10% Owner

Transactions

Exercise/Conversion
Common Stock
2021-02-25$2.30/sh+47,000$108,100→ 233,515 total
Exercise/Conversion
Stock Option (right to buy)
2021-02-25−47,000→ 63,236 total
Exercise: $2.30Exp: 2024-10-02→ Common Stock (47,000 underlying)

Footnotes (2)

[F1]Includes 99,666 unvested RSUs.
[F2]The option was fully vested.

Documents

1 file

4
edgar.xmlPrimary
FORM 4 -

Issuer

Kala Pharmaceuticals, Inc.

CIK 0001479419

Entity typeother

Related Parties

1

filerCIK 0001710697

Filing Metadata

Form type: 4
Filed: Feb 25, 7:00 PM ET
Accepted: Feb 26, 5:35 PM ET
Size: 6.6 KB

View on SEC.gov